Akero Therapeutics CDO sells shares worth over $230,000 By Investing.com

In a recent move at Akero Therapeutics, Inc. (NASDAQ:), Chief Development Officer Yale Catriona sold a total of 8393 shares of the company’s common stock, garnering over $230,000. This sale occurred over three separate transactions on September 16, 17, and 18.

The shares were sold at weighted-average prices that ranged from $27.515 to $27.56, with the transactions conducted under a pre-arranged 10b5-1 trading plan. This plan allows company insiders to set up a predetermined schedule for buying and selling shares at a time when they are not in possession of material non-public information, thereby helping to avoid any accusations of insider trading.

On September 16, Catriona sold 2485 shares at an average price of $27.515. The following day, an additional 2037 shares were sold at an average price of $27.548. The final sale on September 18 comprised 3871 shares at an average price of $27.56. The total value of the shares sold across these three dates amounted to approximately $231,174.

In addition to the sales, Catriona also acquired shares through the exercise of stock options across the same dates. On September 16, 2485 shares were acquired at $0.615 per share, followed by 2037 shares on September 17, and 3871 shares on September 18, all at the same price. The total expenditure for these option exercises was $5,161.

The transactions were disclosed to the U.S. Securities and Exchange Commission in a Form 4 filing, which provides transparency into the trading activities of a company’s officers and directors, and can offer investors insights into management’s perspective on the firm’s prospects.

Akero Therapeutics continues to focus on its mission in the pharmaceutical preparations sector, with these transactions forming part of the regular financial activities of its executives.

In other recent news, Akero Therapeutics has made significant progress in its Phase 3 trial for a treatment aimed at MASH patients with compensated cirrhosis. The trial, named SYNCHRONY Outcomes, is evaluating the efficacy of efruxifermin (EFX) in patients with fibrosis stage 4 (F4). This development follows the announcement that the first patient has been dosed in the study.

The SYNCHRONY Outcomes trial plans to enroll approximately 1,150 F4 MASH patients, with the primary endpoint being to assess fibrosis regression without worsening of MASH after a 96-week treatment period. Key secondary endpoints such as improvements in glycemic control and lipid levels will also be monitored.

H.C. Wainwright has maintained a Buy rating and a $50.00 stock price target for Akero, reflecting a positive outlook on the company’s therapeutic developments. Investors are eagerly awaiting the Week 96 data release from the ongoing Phase 2b SYMMETRY study, expected in the first quarter of 2025, which will provide insights into the long-term effects of EFX on F4 MASH patients.

InvestingPro Insights

Following the recent transactions by Akero Therapeutics, Inc.’s (NASDAQ:AKRO) Chief Development Officer, investors might be keen to understand the company’s financial health and market performance. Akero Therapeutics, with a market capitalization of $1.87 billion, is navigating through a challenging phase as suggested by its negative P/E ratio of -7.99, indicating that the market currently has a pessimistic view of its earnings potential.

An InvestingPro Tip worth noting is that Akero holds more cash than debt on its balance sheet, which can be a sign of financial stability and provides the company with a cushion to fund operations and strategic initiatives. However, analysts do not anticipate the company to be profitable this year, which is consistent with the negative earnings per share (EPS) of -$3.4 over the last twelve months as of Q2 2024.

Despite this, Akero’s stock has demonstrated a strong return over the last three months, with a 21.66% price total return, outperforming many of its peers. This could signal investor confidence in its future prospects or a reaction to recent developments within the company. Nevertheless, potential investors should be aware that the stock price often moves in the opposite direction of the market, which could imply higher volatility and risks.

For those looking for more in-depth analysis, InvestingPro offers additional insights, including 9 more InvestingPro Tips, which can be found at https://www.investing.com/pro/AKRO. These tips provide a comprehensive look at the company’s financials, market performance, and expert analyst opinions, which can be invaluable for making informed investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.